FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
News|Videos|May 20, 2023
Looking Toward the Future of American Psychiatry
Author(s)Petros Levounis, MD, MA
Petros Levounis, MD, MA, reflects on his upcoming presidency for the American Psychiatric Association.
Advertisement
CONFERENCE REPORTER
The American Psychiatric Association (APA) President Elect,
Dr Levounis is Presiddent Elect of the APA; professor and chair of the Department of Psychiatry at Rutgers New Jersey Medical School; chief of service at University Hospital in Newark, New Jersey; and the author of 13+ books.
Advertisement
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
3
Treating PTSD Among Veterans at Risk for Suicide
4
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
5